BLUEPRINT MEDICINES CORP
NASDAQ: BPMC (Blueprint Medicines Corporation)
Last update: yesterday, 2:37PM129.46
0.18 (0.14%)
| Previous Close | 129.28 |
| Open | 129.35 |
| Volume | 2,924,184 |
| Avg. Volume (3M) | 3,765,949 |
| Market Cap | 8,371,673,600 |
| Price / Sales | 14.62 |
| Price / Book | 24.41 |
| 52 Weeks Range | |
| Earnings Date | 30 Jul 2025 - 4 Aug 2025 |
| Profit Margin | -27.70% |
| Operating Margin (TTM) | -27.50% |
| Diluted EPS (TTM) | -2.51 |
| Quarterly Revenue Growth (YOY) | 55.50% |
| Quarterly Earnings Growth (YOY) | -99.40% |
| Total Debt/Equity (MRQ) | 208.50% |
| Current Ratio (MRQ) | 2.80 |
| Operating Cash Flow (TTM) | -145.55 M |
| Levered Free Cash Flow (TTM) | -20.78 M |
| Return on Assets (TTM) | -9.75% |
| Return on Equity (TTM) | -47.71% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Blueprint Medicines Corporation | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | -2.5 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 2.0 |
| Average | -0.88 |
|
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 0.88% |
| % Held by Institutions | 109.19% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 135.00 (Scotiabank, 4.28%) | Hold |
| 135.00 (Stephens & Co., 4.28%) | Hold | |
| Median | 129.00 (-0.36%) | |
| Low | 129.00 (Wells Fargo, -0.36%) | Hold |
| 129.00 (UBS, -0.36%) | Hold | |
| 129.00 (Morgan Stanley, -0.36%) | Hold | |
| 129.00 (Citigroup, -0.36%) | Hold | |
| 129.00 (JP Morgan, -0.36%) | Hold | |
| 129.00 (Wedbush, -0.36%) | Hold | |
| Average | 130.44 (0.76%) | |
| Total | 9 Hold | |
| Avg. Price @ Call | 127.88 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Wells Fargo | 17 Jun 2025 | 129.00 (-0.36%) | Hold | 128.23 |
| Morgan Stanley | 05 Jun 2025 | 129.00 (-0.36%) | Hold | 127.90 |
| UBS | 05 Jun 2025 | 129.00 (-0.36%) | Hold | 127.90 |
| Citigroup | 04 Jun 2025 | 129.00 (-0.36%) | Hold | 128.10 |
| Stephens & Co. | 03 Jun 2025 | 135.00 (4.28%) | Hold | 127.60 |
| JP Morgan | 02 Jun 2025 | 129.00 (-0.36%) | Hold | 127.79 |
| Needham | 02 Jun 2025 | 130.00 (0.42%) | Hold | 127.79 |
| Scotiabank | 02 Jun 2025 | 135.00 (4.28%) | Hold | 127.79 |
| Wedbush | 02 Jun 2025 | 129.00 (-0.36%) | Hold | 127.79 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |